PROC Key Statistics, Chart & Performance
The current stock price of PROC is 1.01 USD. In the past month the price decreased by -56.65%. In the past year, price decreased by -68.92%.
PROC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PROC. When comparing the yearly performance of all stocks, PROC is a bad performer in the overall market: 96.48% of all stocks are doing better.
PROC Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PROC Forecast & Estimates
6 analysts have analysed PROC and the average price target is 5.1 USD. This implies a price increase of 404.95% is expected in the next year compared to the current price of 1.01.
PROC Ownership
About PROC
Company Profile
Procaps Group SA is an international healthcare and pharmaceutical company. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.
Company Info
PROCAPS GROUP SA
9, rue de Bitbourg
Luxembourg LU
CEO: Kyle P. Bransfield
Employees: 5500
PROCAPS GROUP SA / PROC FAQ
What does PROCAPS GROUP SA do?
Procaps Group SA is an international healthcare and pharmaceutical company. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.
Can you provide the latest stock price for PROCAPS GROUP SA?
The current stock price of PROC is 1.01 USD. The price decreased by -36.51% in the last trading session.
Does PROC stock pay dividends?
PROC does not pay a dividend.
What is the ChartMill rating of PROCAPS GROUP SA stock?
PROC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of PROC stock?
PROCAPS GROUP SA (PROC) operates in the Health Care sector and the Pharmaceuticals industry.